IPOPI was invited along with other stakeholders, local guests and dignitaries to attend a dedication ceremony of Kedrion’s facility in Melville, New York. Martine Pergent (IPOPI Vice-Chair) attended on behalf of IPOPI, along with other PID patient representative, John Boyle (IDF). The celebration marked the launch of a state-of-the-art production line for the manufacturing of anti-D immunoglobulin therapies as well as Kedrion’s increasing global activities.
“We started our activity in the United States of America eleven years ago, opening three collection centers,” stated Paolo Marcucci, Chairman and CEO of Kedrion. “Then in 2011, we reinforced our presence with the acquisition of the United States facility. The growth of Kedrion in this country has been constant and significant year by year.” The ceremony was also an opportunity to celebrate plasma donors who were in attendance. Tribute was paid to their continuous gift for life which is key to produce plasma-derived medicinal products for patients living with rare plasma related disorders such as PID or haemophilia.
Kedrion is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived medicinal products.